Key Strategies for Overcoming Barriers to HCV Elimination Among Men Who Have Sex With Men
  • CME
  • CE

This CME/CE-certified interactive video module provides in-depth expert perspectives on barriers impeding expanded treatment and cure of HCV infection among men who have sex with men along with an analysis of critical strategies for preventing HCV infection and promoting sexual health.
Mark S. Sulkowski, MD
Program Director
Daniel Fierer Headshot
Daniel S. Fierer, MD
W. David Hardy, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Registered Nurses: 1.9 Nursing contact hours
Pharmacists: 2.0 contact hours (0.2 CEUs)
Released: April 16, 2019 Expiration: April 15, 2020
Multimedia Key Strategies for Overcoming Barriers to HCV Elimination Among Men Who Have Sex With Men
This program is divided into short segments. After reviewing all segments, click the Claim Credit button to complete the CME posttest and evaluation.
Introduction
See an overview of the activity and meet the faculty experts.
Launch Introduction
Case 1: MSM With HIV and Chronic HCV Coinfection
Gain an understanding of HCV as a sexually transmitted infection among MSM and learn how applying HCV treatment-as-prevention concepts can help to overcome barriers to expanded treatment of HCV infection among MSM living with HIV infection.
Launch Case 1: MSM With HIV and Chronic HCV Coinfection
Case 2: MSM Living With HIV Experiences HCV Reinfection After Achieving SVR to HCV Therapy
Learn the best approaches for HCV screening in MSM living with HIV infection, including those who have been cured of previous HCV infection, and important considerations for addressing acute HCV infection among MSM.
Launch Case 2: MSM Living With HIV Experiences HCV Reinfection After Achieving SVR to HCV Therapy
Case 3: HIV-Negative MSM Receiving PrEP Acquires HCV Infection
Consider the important roles of periodic HCV screening and counseling on HCV sexual transmission risk for MSM receiving HIV pre-exposure prophylaxis.
Launch Case 3: HIV-Negative MSM Receiving PrEP Acquires HCV Infection

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Devise strategies to overcome barriers to HCV treatment for MSM with HCV/HIV coinfection
  • Apply interventions that support HCV elimination efforts among MSM at high risk for onward transmission
  • Provide appropriate patient counsel on HCV reinfection risk and prevention strategies for MSM who are cured of current HCV infection

Acknowledgements

Jointly provided by

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Endorsed by
This activity is supported by independent educational grants from
AbbVie
Gilead Sciences

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Mark S. Sulkowski, MD

Professor of Medicine
Medical Director,
Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology/Hepatology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Merck & Co, Inc, and funds for research support (paid to Johns Hopkins University) from AbbVie, Assembly Bio, Gilead Sciences, and Proteus Digital Health.

Faculty

Daniel S. Fierer, MD

Associate Professor
Department of Infectious Diseases
Icahn School of Medicine at Mount Sinai
Head, Co-infection Clinic
Jack Martin Fund
Mount Sinai Medical Center
New York, New York

Daniel S. Fierer, MD, has disclosed that he has received funds for research support and has ownership interest in Gilead Sciences.
W. David Hardy, MD

Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Washington, DC

W. David Hardy, MD, has disclosed that he has received consulting fees from Gilead Sciences, Merck & Co, Inc, and ViiV Healthcare and funds for research support (paid to his former institution) from Amgen, Gilead Sciences, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

The ASAM planners and managers have nothing to disclose.

The INHSU planners and managers have nothing to disclose.

The HealthHCV planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Goal

The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, American Society of Addiction Medicine, International Network for Hepatitis in Substance Users and HealthHCV.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.9 contact hours.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-749-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 16, 2019, through April 15, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Audio from CCO faculty Dr. Nancy Reau on strategies to address gaps in viral hepatitis care: learn how to prevent HAV and HBV, how to screen for and treat HCV

Nancy Reau, MD Released: December 3, 2019

Downloadable slides on data from AALSD 2019 selected by expert faculty as relevant to care of patients with viral hepatitis or NAFLD/NASH, as reported by Clinical Care Options.

Ira M. Jacobson, MD Nancy Reau, MD Released: December 2, 2019

Downloadable slides from CCO and Dr. Nancy Reau on addressing gaps in viral hepatitis care: expert tips on managing HAV, HBV, HCV and on new AASLD guidance

Nancy Reau, MD Released: November 25, 2019

Clinical Care Options’ (CCO) expert audio analysis of new viral hepatitis data from AASLD 2019, provided by Norah Terrault, MD, MPH

Norah Terrault Headshot Norah Terrault, MD, MPH Released: November 22, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?